precisionmedicineonline20h
Intellia Readying for Commercial Activities, First Product Launch in 2027
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
precisionmedicineonline15h
First Ascent Biomedical Nabs $6M Investment to Advance Functional Precision Medicine Platform
The firm will use the funds to establish a commercial lab and continue advancing its AI- and sequencing-based platform for personalizing cancer treatment.
precisionmedicineonline16h
Hutchmed's Orpathys Approved in China for First-Line MET-Altered NSCLC
This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.
precisionmedicineonline19h
Eli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5B
NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.
precisionmedicineonline17h
FDA Accepts Eisai's BLA for Subcutaneous Leqembi Maintenance Dosing
The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.